Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YXZQL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-15
|
|||||
| Synonyms |
SGN-15; BMS-182248; cBR96-Dox; cBR96-doxorubicin immunoconjugate; BMS-182248-01; BR96-doxorubicin conjugate
Click to Show/Hide
|
|||||
| Organization |
Bristol-Myers Squibb (Top20 MNC) (Originator) (No Rights);Seagen (Top20 MNC)
|
|||||
| Drug Status |
Phase 2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
CBR96
|
Antibody Info | ||||
| Antigen Name |
Lewis Y
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Acid-labile linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Non-small cell lung carcinoma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic/unresectable recurrent breast carcinoma with ≤2 prior chemotherapy regimens for metastatic disease or recurrence within 6 months post-adjuvant therapy, measurable disease/bone markers (2×ULN) with Lewis-y antigen expression, and no active brain metastases.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00028483 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
The study included patients with metastatic or recurrent NSCLC who failed 1-2 prior therapies or recurred within 6 months post-adjuvant chemo, requiring Lewis-y antigen expression and measurable/evaluable disease with ECOG ≤2 and ≥3-month life expectancy, excluding those with prior docetaxel, high anthracycline exposure, active infections, uncontrolled comorbidities, or CNS metastases.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051571 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed stage IIIB/IV NSCLC with ≥1 measurable lesion, no prior metastatic chemotherapy, ECOG ≤2, available tumor block for LeY antigen testing, approved FDG-PET, and adequate organ function, excluding candidates for curative combined therapy.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00086333 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed advanced/recurrent ovarian cancer with 2-3 prior therapy failures, ≥20% Lewis-y antigen expression, LVEF>50%, and platinum resistance (progression during/first 6 months post-treatment).
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051584 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Eligible patients had hormone-refractory prostate cancer with disease progression evidenced by tumor growth or rising PSA with metastatic disease, plus documented Lewis (Y) antigen expression via immunohistochemistry on tumor samples.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00031187 | Clinical Status | PHASE2 | ||
| Clinical Description | Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma | ||||
References